PLT Health Solutions, in collaboration with Laila Nutraceuticals, has announced the completion of a second clinical study on its next-generation Dynagenix Muscle+Joint Formula.
Dynagenix is an innovative, low-dose Boswellia serrata extract in a neutral-tasting, water-soluble form, making it ideal for formulating into contemporary delivery systems.
The newest study demonstrated that just 40 mg/day of Dynagenix led to statistically significant improvements in joint comfort, stiffness and function as early as five days after initial supplementation.
Within 15 days, participants experienced enhanced flexibility and improved physical performance, with the 30-day results showing compelling gains across a broad range of mobility metrics.
Previous studies on Dynagenix have demonstrated its effectiveness, not only for joint discomfort but also for next-day muscle and joint recovery after exercise.
They have shown significantly reduced muscle soreness and recovery of strength for a total musculoskeletal solution.
“This second clinical study validates Dynagenix as a true category-advancing ingredient,” said Seth Flowerman, CEO of PLT Health Solutions.
“It offers fast, meaningful results in joint and muscle comfort — whether you're an athlete returning to activity or someone looking to move through daily life with less discomfort and more ease."
"Plus, thanks to its low-dose, water-soluble form, it offers exciting innovation potential for formulators."
The results: enhanced function in just five days
The randomised, double-blind, placebo-controlled study evaluated 72 men and women (age 40-70) with Grade II osteoarthritis.
Subjects received either 40 mg/day of Dynagenix or a matching placebo for 30 days.
Key outcome measures tested were WOMAC pain, stiffness and function, as well as a 30-second Chair Stand Test, a 6-minute Walk Test, a Stair Climb Test and knee flexion and range of motion.
Biomarkers of inflammation were also evaluated.
Based on the WOMAC scale, subjects consuming Dynagenix experienced the following effects:
- joint comfort improved by 47%,
- joint stiffness reduced by 47%,
- joint function improved by 45%,
- and 46% saw an improvement in overall joint health.
- a 25% increase in Chair Stand Test performance at two weeks,
- stair navigation was 25% faster (4 seconds faster),
- a 15.4% increase in walking speed, with subjects walking 47 meters farther in six minutes,
- and a 14% improvement in flexibility.
Expanded clinical platform: from recovery to resilience
This new study builds on a 2019 clinical trial using a Delayed Onset Muscle Soreness (DOMS) model in recreationally active men.
That study showed that 60 mg/day of Dynagenix significantly reduced muscle soreness, reduced joint soreness during exercise, increased strength recovery, lowered perceived exertion and improved inflammatory biomarkers related to muscle and connective tissue stress.
"Dynagenix now has robust data across two different populations and usage occasions," said Jennifer Murphy, Director of Innovation & Clinical Development at PLT.
"From reducing soreness and accelerating recovery post-exercise to improving everyday joint function in older adults, Dynagenix delivers fast, measurable benefits at a very low 40mg effective dose."
“At PLT, we are enthusiastic about how these results will allow brands to deliver superior joint health support across a wider range of palatable, easy-to-consumer products in consumer-preferred formats such as gummies, shots, sachets and stick-packs and expand its potential for helping people live happier, healthier lives,” she added.
